Human methylome studies SRP229996 Track Settings
 
Stem and effector CD8 T-cells from human cancers [Blood, Kidney Tumor]

Track collection: Human methylome studies

+  All tracks in this collection (455)

Maximum display mode:       Reset to defaults   
Select views (Help):
CpG reads ▾       CpG methylation ▾       HMR       PMD       AMR      
Select subtracks by views and experiment:
 All views CpG reads  CpG methylation  HMR  PMD  AMR 
experiment
SRX7142043 
SRX7142044 
SRX7142045 
SRX7142046 
SRX7142047 
SRX7142048 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 Configure
 SRX7142043  CpG reads  Kidney Tumor / SRX7142043 (CpG reads)   Schema 
hide
 Configure
 SRX7142043  CpG methylation  Kidney Tumor / SRX7142043 (CpG methylation)   Schema 
hide
 SRX7142043  HMR  Kidney Tumor / SRX7142043 (HMR)   Schema 
hide
 SRX7142043  PMD  Kidney Tumor / SRX7142043 (PMD)   Schema 
hide
 SRX7142043  AMR  Kidney Tumor / SRX7142043 (AMR)   Schema 
hide
 Configure
 SRX7142044  CpG reads  Kidney Tumor / SRX7142044 (CpG reads)   Schema 
hide
 Configure
 SRX7142044  CpG methylation  Kidney Tumor / SRX7142044 (CpG methylation)   Schema 
hide
 SRX7142044  HMR  Kidney Tumor / SRX7142044 (HMR)   Schema 
hide
 SRX7142044  PMD  Kidney Tumor / SRX7142044 (PMD)   Schema 
hide
 SRX7142044  AMR  Kidney Tumor / SRX7142044 (AMR)   Schema 
hide
 Configure
 SRX7142045  CpG reads  Kidney Tumor / SRX7142045 (CpG reads)   Schema 
hide
 Configure
 SRX7142045  CpG methylation  Kidney Tumor / SRX7142045 (CpG methylation)   Schema 
hide
 SRX7142045  HMR  Kidney Tumor / SRX7142045 (HMR)   Schema 
hide
 SRX7142045  PMD  Kidney Tumor / SRX7142045 (PMD)   Schema 
hide
 SRX7142045  AMR  Kidney Tumor / SRX7142045 (AMR)   Schema 
hide
 Configure
 SRX7142046  CpG reads  Kidney Tumor / SRX7142046 (CpG reads)   Schema 
hide
 Configure
 SRX7142046  CpG methylation  Kidney Tumor / SRX7142046 (CpG methylation)   Schema 
hide
 SRX7142046  HMR  Kidney Tumor / SRX7142046 (HMR)   Schema 
hide
 SRX7142046  PMD  Kidney Tumor / SRX7142046 (PMD)   Schema 
hide
 SRX7142046  AMR  Kidney Tumor / SRX7142046 (AMR)   Schema 
hide
 Configure
 SRX7142047  CpG reads  Blood / SRX7142047 (CpG reads)   Schema 
hide
 Configure
 SRX7142047  CpG methylation  Blood / SRX7142047 (CpG methylation)   Schema 
hide
 SRX7142047  HMR  Blood / SRX7142047 (HMR)   Schema 
hide
 SRX7142047  PMD  Blood / SRX7142047 (PMD)   Schema 
hide
 SRX7142047  AMR  Blood / SRX7142047 (AMR)   Schema 
hide
 Configure
 SRX7142048  CpG reads  Blood / SRX7142048 (CpG reads)   Schema 
hide
 Configure
 SRX7142048  CpG methylation  Blood / SRX7142048 (CpG methylation)   Schema 
hide
 SRX7142048  HMR  Blood / SRX7142048 (HMR)   Schema 
hide
 SRX7142048  PMD  Blood / SRX7142048 (PMD)   Schema 
hide
 SRX7142048  AMR  Blood / SRX7142048 (AMR)   Schema 
    

Study title: Stem and effector CD8 T-cells from human cancers
SRA: SRP229996
GEO: GSE140430
Pubmed: 31827286

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX7142043 Kidney Tumor 0.743 5.6 30626 1455.1 278 987.7 125 37067.8 0.972 title: GSM4161227 Kidney_ef_1, Homo sapiens, Bisulfite-Seq; source_name: Kidney_ef; tissue: Kidney tumor; cell_type: CD8 T-cell; cell_subtype: Cd8+PD1+Tim3+
SRX7142044 Kidney Tumor 0.744 3.6 27719 1623.7 98 1015.9 65 73772.6 0.973 title: GSM4161228 Kidney_ef_2, Homo sapiens, Bisulfite-Seq; source_name: Kidney_ef; tissue: Kidney tumor; cell_type: CD8 T-cell; cell_subtype: Cd8+PD1+Tim3+
SRX7142045 Kidney Tumor 0.707 5.7 27164 1678.3 416 936.9 62 45966.0 0.973 title: GSM4161229 Kidney_stem_1, Homo sapiens, Bisulfite-Seq; source_name: Kidney_stem; tissue: Kidney tumor; cell_type: CD8 T-cell; cell_subtype: Cd8+CD28+PD1+Tim3-
SRX7142046 Kidney Tumor 0.728 4.9 27731 1618.5 475 1038.5 69 53211.0 0.972 title: GSM4161230 Kidney_stem_2, Homo sapiens, Bisulfite-Seq; source_name: Kidney_stem; tissue: Kidney tumor; cell_type: CD8 T-cell; cell_subtype: Cd8+CD28+PD1+Tim3-
SRX7142047 Blood 0.814 8.8 45239 1108.8 712 1033.3 1427 26247.5 0.972 title: GSM4161231 Naive_1, Homo sapiens, Bisulfite-Seq; source_name: Naive; tissue: Blood; cell_type: CD8 T-cell; cell_subtype: CD8+CCR7+CD45RA+
SRX7142048 Blood 0.813 9.2 45887 1094.3 823 1013.4 1490 25943.7 0.974 title: GSM4161232 Naive_2, Homo sapiens, Bisulfite-Seq; source_name: Naive; tissue: Blood; cell_type: CD8 T-cell; cell_subtype: CD8+CCR7+CD45RA+

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.